Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.6.5, replacing Revision: v3.6.4. This appears to be a routine site version update affecting only the underlying code/version label, not the study details.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedNew PubMed-listed publication citation was added to the Publications section (Cancer Res Commun. 2026) for the study. A PubMed auto-fill note with revision 3.6.4 was also included, clarifying the source of automatically pulled text.SummaryDifference0.2%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision tag in the page footer updated to Revision: v3.6.3, replacing the previous Revision: v3.6.2. This reflects a minor metadata update to the page without changing study content or eligibility details.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page's revision tag has been updated from v3.6.0 to v3.6.2, reflecting a newer build version.SummaryDifference0.1%

- Check59 days agoChange DetectedNew user guidance and join-related navigation items have been added (Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, How to Join a Study). The label formatting for Intervention/Treatment was updated, and a site revision note (Revision: v3.6.0) is shown.SummaryDifference0.5%

- Check66 days agoChange DetectedRevision: v3.5.5 is now displayed, replacing v3.5.4. This reflects a small update to the page's version/build tag rather than changes to the study details.SummaryDifference0.1%

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.